Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.

Ph pharmaceuticals is a leading peer-reviewed journal published by MDPI, focused on the dynamic fields of pharmaceutical science, drug discovery, and molecular medicine. Since its inception, the journal has established itself as a vital resource for researchers and practitioners, boasting an impressive impact factor reflected in its Q1 and Q2 quartile rankings across multiple categories, including Pharmaceutical Science and Drug Discovery. As an open access journal since 2009, Pharmaceuticals promotes the dissemination of cutting-edge research and innovative findings globally, facilitating collaboration and knowledge sharing among scientists. With a robust ranking in Scopus, specifically at Rank #56 in Pharmaceutical Science and Rank #65 in Drug Discovery, the journal serves as a critical platform for advancing the field and supporting future developments in therapeutics and pharmaceuticals. Based in Switzerland, Pharmaceuticals continues to inspire a diverse readership of scholars and healthcare professionals who are dedicated to improving health outcomes through innovative research.

Ars Pharmaceutica is a distinguished open-access journal published by UNIV GRANADA, EDITORIAL, that has been at the forefront of pharmaceutical sciences since its establishment. With ISSN 0004-2927 and E-ISSN 2340-9894, this journal aims to disseminate high-quality research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of the field. With a historical scope that spans from 1980 to 2017, it has played a pivotal role in shaping the discourse surrounding pharmaceutical science and its intersection with the arts and humanities. Although currently ranked within the 13th percentile in Scopus for Pharmaceutical Science and the 11th percentile for History and Philosophy of Science, Ars Pharmaceutica continues to uphold its commitment to academic excellence and innovation. By providing a platform for open-access research, it encourages collaboration and knowledge sharing among researchers, professionals, and students, thus enhancing the broader understanding of pharmaceutical developments and their societal implications.

ACTA POLONIAE PHARMACEUTICA is a well-established peer-reviewed journal published by Polskie Towarzystwo Farmaceutyczne, dedicated to the field of pharmaceutical sciences and pharmacology. With a rich history dating back to 1951, this journal serves as a vital platform for disseminating cutting-edge research and developments in pharmaceutical technology, drug development, and therapeutic therapies. Although it currently operates under a subscription model, its commitment to scientific rigor has earned it a respectable impact factor, placing it in the Q3 and Q4 quartiles respectively for Pharmaceutical Science and Pharmacology as of 2023. Researchers and practitioners alike will find value in its comprehensive coverage of essential topics, as well as its diverse range of contributions from both established and emerging scholars in the field. With its address located in the heart of Warsaw, Poland, ACTA POLONIAE PHARMACEUTICA aims to further bridge the gap between academia and industry, paving the way for innovation in drug discovery and therapeutic applications.

The European Journal of Pharmaceutical Sciences is a prestigious academic journal dedicated to advancing the field of pharmaceutical science. Published by Elsevier, the journal boasts an impressive impact factor and is categorized in the Q1 quartile for pharmaceutical science as of 2023, signifying its influence and reputation within the academic community. With a Scopus ranking of #20 out of 183 in the fields of pharmacology, toxicology, and pharmaceutics, the journal provides a vital platform for researchers and practitioners to disseminate innovative studies and groundbreaking research that push the boundaries of drug development and delivery. Based in the Netherlands and operating since 1993, the journal seeks to cover a broad scope of topics related to pharmaceutical sciences, encouraging rigorous evaluations and discussions that enhance the understanding and application of this critical field. The absence of open access underscores the commitment to maintaining high scholarly standards, while still offering avenues for libraries and institutions to provide access to cutting-edge research. As the journal converges towards its 2024 milestones, it continuously aims to foster a vibrant exchange of knowledge among its diverse readership, comprising committed researchers, professionals, and students.

European Journal of Pharmaceutics and Biopharmaceutics is a leading academic journal published by Elsevier, dedicated to advancing the field of pharmaceutical sciences through high-quality research. Established in 1991, this multidisciplinary journal offers a platform for the dissemination of innovative findings in pharmaceutics and biopharmaceutics, covering crucial aspects such as drug formulation, delivery systems, and the interface of pharmaceutical formulation with biological systems. The journal is well-regarded for its impact, earning a Q1 status in Pharmaceutical Science and consistent Q2 rankings in both Biotechnology and Medicine (Miscellaneous) categories in 2023, thereby highlighting its significance in the scientific community. With an impressive Scopus ranking of 26th percentile in Pharmaceutical Science and 60th percentile in Biotechnology, it positions itself firmly at the forefront of research, supporting researchers, professionals, and students in their quest to address complex health challenges. While the journal does not offer an open-access option, it facilitates a rigorous peer-review process, ensuring that published articles meet the highest standards of scientific integrity. For those looking to make meaningful contributions to the field, the European Journal of Pharmaceutics and Biopharmaceutics serves as an essential resource and reference point.

Pharmaceutical Chemistry Journal is a pivotal publication in the field of pharmaceutical sciences, renowned for its in-depth articles and research findings. Published by Springer in the United States, this journal provides a crucial platform for researchers, students, and professionals dedicated to advancing drug discovery and pharmacology. With an ISSN of 0091-150X and an E-ISSN of 1573-9031, this journal has consistently aimed to promote scholarly communication and innovation within its scope since its inception in 1967. Despite its current Category Quartiles ranking of Q4 in both Drug Discovery and Pharmacology, the journal remains a valuable resource for disseminating new ideas and findings that contribute to the scientific community. Researchers benefit from the journal's commitment to high-quality peer-reviewed content, even in an environment where open access options are currently not available. As the field evolves, the Pharmaceutical Chemistry Journal continues to play an important role in shaping future advancements in drug development and safety.

Expert Opinion on Drug Delivery is a leading journal in the field of pharmaceutical science, published by Taylor & Francis Ltd. With an impressive impact factor and a prestigious Q1 ranking in 2023, it stands out as a vital resource for researchers, professionals, and students dedicated to advancing drug delivery technologies. Established in 2004, the journal has consistently provided a platform for critical insights and expert analyses, bridging the gap between innovation and application in drug delivery systems. Although it currently does not offer Open Access options, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to the fields of pharmacology, toxicology, and pharmaceutics. With its robust ranking of 13th out of 183 in Scopus, the journal continues to foster discourse and collaboration among experts, thereby enhancing the advancement of therapeutic options and improving patient outcomes.

Journal of Research in Pharmacy, published by Marmara University, serves as a pivotal platform for the dissemination of innovative research in the field of pharmacology and pharmaceutical sciences. With an ISSN of 2630-6344 and an E-ISSN of the same, this journal is dedicated to publishing high-quality research spanning various aspects of pharmacology, toxicology, and pharmaceutics. The journal, categorized in Q3 for both pharmacology (medical) and miscellaneous pharmacology, toxicology, and pharmaceutics in 2023, showcases the ongoing evolution of these disciplines amid growing scientific inquiry. As of now, it ranks #56/80 in general pharmacology, toxicology and pharmaceutics, spotlighting its relevance within the academic community. Although it operates under a traditional access model, the journal is committed to providing researchers, professionals, and students with a comprehensive understanding of contemporary challenges and innovations in pharmacy research. Established in 2019, it continues to foster academic dialogue and contribute significantly to the advancement of pharmacological sciences until at least 2024. For all interested in cutting-edge pharmaceutical research, this journal presents an invaluable resource from its base in Istanbul, Turkey.